A Prognostic Signature For Breast Cancer
SUMMARY
This prognostic signature for breast cancer improves patient survival outcomes by assessing the coordinated regulation of HMGA2, TET1, and HOXA9 expression to guide targeted therapeutic interventions and prognostication.
The Unmet Need: Accurate prognostic tools for guiding breast cancer treatment decisions remain insufficiently developed and clinically implemented
- Breast cancer affects over 230,000 new patients annually in the United States, posing significant challenges in personalized treatment decisions due to tumor heterogeneity and variability in patient outcomes; current diagnostic approaches often lack sufficient precision to predict survival or identify patients likely to respond to specific therapies such as DNA demethylation agents.
- Emerging trends in oncology emphasize biomarker-driven diagnostics and companion therapeutics, leveraging molecular signatures to tailor patient management strategies and improve clinical efficacy, thus creating opportunities for advanced molecular prognostic tools that integrate epigenetic and gene expression profiles.
The Proposed Solution: Prognostic signature combining coordinated HMGA2, TET1, and HOXA9 gene expression profiling to stratify breast cancer patient survival and therapeutic response
- The faculty inventor developed a gene expression signature reflecting the coordinated regulation of HMGA2, TET1, and HOXA9, which collectively serve as prognostic indicators for breast cancer patient survival; the approach facilitates identification of patients with suppressed TET1/HOXA9 signaling who may benefit from induction therapies or DNA demethylation agents, and inhibition of HMGA2 as a therapeutic target. This signature differs from existing methods by integrating epigenetic regulators with oncogenic markers, and although a diagnostic kit is yet to be developed and validated clinically, its broad applicability across breast cancer subtypes supports its potential utility in companion diagnostic
applications.
ADVANTAGES
- Improved patient survival prognostication
- Identification of treatment-responsive patient subpopulations
- Molecular signature integrating epigenetic and oncogenic markers
- Potential companion diagnostic for DNA demethylation agents
- Broad applicability across breast cancer subtypes
- Non-invasive prognostic evaluation capability
APPLICATIONS
- Breast cancer prognosis stratification
- Guidance of DNA demethylation therapeutic interventions
- Predictive evaluation for epigenetic-targeted treatment suitability